John M. Bedtelyon

Array ( [id] => 17881250 [patent_doc_number] => 20220296727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => Immunoconjugate [patent_app_type] => utility [patent_app_number] => 17/631259 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398845 [patent_doc_number] => 20200339703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE [patent_app_type] => utility [patent_app_number] => 16/925824 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17814306 [patent_doc_number] => 11419893 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Method of producing a designer blood product, method of using a designer blood product, and diet for selectively enhancing blood profile [patent_app_type] => utility [patent_app_number] => 16/902560 [patent_app_country] => US [patent_app_date] => 2020-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17934 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482518 [patent_doc_number] => 20200376118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => A B Cell Depleting Agent for the Treatment of Atherosclerosis [patent_app_type] => utility [patent_app_number] => 16/902518 [patent_app_country] => US [patent_app_date] => 2020-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20479396 [patent_doc_number] => 12527860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Compositions for immunotherapy [patent_app_type] => utility [patent_app_number] => 16/891208 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 0 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16891208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421935 [patent_doc_number] => 20200347133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => CD33-Binding Polypeptides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/864480 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867056 [patent_doc_number] => 20220289791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => LACTATE DEHYDROGENASE INHIBITOR POLYPEPTIDES FOR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/608002 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20535793 [patent_doc_number] => 12552857 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Method for separation of antibodies or antibody fragments being devoid of an Fc region capable of binding to protein A [patent_app_type] => utility [patent_app_number] => 17/604964 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 1101 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525294 [patent_doc_number] => 20200399374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => Anti-PD-1 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/845805 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656086 [patent_doc_number] => 20210052722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => PEANUT FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/842675 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16842675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685893 [patent_doc_number] => 20220193185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => COMBINATION OF SYNTHETIC PEPTIDES WITH AFFINITY TO THE TGF-ss RECEPTOR AND WITH AFFINITY TO THE IL-10 RECEPTOR, PHARMACEUTICAL COMPOSITION AND THEIR USE AS IMMUNOMODULATORS IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR ALLERGIC DISEASES [patent_app_type] => utility [patent_app_number] => 17/601628 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641999 [patent_doc_number] => 20220169737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSIS [patent_app_type] => utility [patent_app_number] => 17/601359 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545333 [patent_doc_number] => 11718673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein [patent_app_type] => utility [patent_app_number] => 16/836197 [patent_app_country] => US [patent_app_date] => 2020-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 62 [patent_no_of_words] => 11723 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 223 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328420 [patent_doc_number] => 20200299386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => T-CELL RECEPTOR (TCR)-BINDING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/834562 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16834562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343594 [patent_doc_number] => 20200308244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => THERAPEUTIC INTERFERON ALPHA 1 PROTEINS [patent_app_type] => utility [patent_app_number] => 16/832995 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -116 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17736009 [patent_doc_number] => 20220221468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => SYSTEMIC ALLERGIC RESPONSE RISK ASSESSMENT IN PEANUT ORAL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/595193 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657117 [patent_doc_number] => 20220177582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => NON-CONSENSUS GLYCOSYLATION OF BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/438209 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087057 [patent_doc_number] => 20200197515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => METHOD OF INDUCING TOLERANCE TO AN ALLERGEN [patent_app_type] => utility [patent_app_number] => 16/805035 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611551 [patent_doc_number] => 20220153830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Manufacturing Methods for Producing Anti-TNF Antibody Compositions [patent_app_type] => utility [patent_app_number] => 17/438702 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18462442 [patent_doc_number] => 11686728 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-27 [patent_title] => Method for presymptomatic diagnosis of coeliac disease and gluten sensitivity [patent_app_type] => utility [patent_app_number] => 16/793432 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 14 [patent_no_of_words] => 5596 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16793432 [rel_patent_id] =>[rel_patent_doc_number] =>)